Elanco (ELAN) Animal Health announced its latest entry into the canine dermatology space with the USDA approval of Befrena, a new anti-IL31 monoclonal antibody injection targeting canine allergic and atopic dermatitis. Befrena is recommended at a dosing interval of 6 to 8 weeks post-treatment, which stands in contrast to the 4 to 8 weeks of the current market competitor, lokivetmab. Elanco continues to expect to launch Befrena in the first half of 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Elanco’s Credelio Quattro tablets granted FDA conditional approval
- Elanco price target raised to $22 from $18 at Morgan Stanley
- Closing Bell Movers: Ford nudges higher raised outlook, EV charge
- Elanco CEO buys $478.5K, CFO buys $150.4K in common stock
- Elanco Animal Health: Strategic Dual Channel Focus and Robust Innovation Pipeline Drive Buy Rating